BeStock  
Stocks › Biotechnology › RXRX

Recursion Pharmaceuticals RXRX

US equityMarket cap rank #2863BiotechnologyAI medical concept stocks
$2.45 −$0.27 (-9.93%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $2.51 +2.39%
Open$2.63
Prev close$2.72
Day range$2.44 – $2.76
Volume29.88M
Market cap$1.53B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±5.2%last 12 reports
Closed higher3 of 1225% of the time
Best reaction+6.8%
Worst reaction-16.6%

Stock move on the day after each report

-16.6%2023/Q4-0.5%2024/Q1+4.2%2024/Q2-0.6%2024/Q3-2.1%2024/Q4-16.6%2025/Q1-4.7%2025/Q2-0.8%2025/Q3+6.8%2025/Q4+1.8%2026/Q1-4.2%2026/Q2-3.9%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q32 Nov 2026After Market±10.9%-3.92%Within range
2026/Q25 Aug 2026Pre Market±8.1%-4.23%Within range
2026/Q16 May 2026Pre Market±8.1%+1.78%Within range
2025/Q425 Feb 2026Pre Market±7.6%+6.80%Within range
2025/Q35 Nov 2025Pre Market±10.6%-0.80%Within range
2025/Q25 Aug 2025Pre Market±13.9%-4.66%Within range
2025/Q15 May 2025Pre Market±16.8%-16.58%Within range
2024/Q428 Feb 2025Pre Market±16.0%-2.09%Within range
2024/Q36 Nov 2024After Market±14.5%-0.57%Within range
2024/Q28 Aug 2024Pre Market±22.8%+4.24%Within range
2024/Q19 May 2024After Market±13.8%-0.46%Within range
2023/Q427 Feb 2024After Market±26.2%-16.62%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q3, ended Sep 2026

Revenue$18.06M+262.3% YoY
Operating profit-$123.18M+28.5% YoY
Net profit-$119.04M+26.6% YoY
Diluted EPS-$0.22+38.9% YoY
Free cash flow-$77.81M+33.8% YoY
Operating cash flow-$77.41M

Revenue, last 8 quarters

$4.5MDec '24$14.8MMar '25$19.1MJun '25$5.0MSep '25$35.4MDec '25$6.3MMar '26$7.3MJun '26$18.1MSep '26

Net profit, last 8 quarters

$-178.9MDec '24$-202.5MMar '25$-171.9MJun '25$-162.3MSep '25$-108.1MDec '25$-117.5MMar '26$-131.0MJun '26$-119.0MSep '26

Profitability & balance sheet

Gross margin27.9%
Operating margin-738.7%
Net margin-709.8%
Return on equity-48.7%
Return on assets-36.3%
Return on invested capital-47.1%
Current ratio5.01
Liabilities / assets25.9%
Cash & investments$549.85M
Total debt$62.44M
Net cash (debt)$487.42M

Discussion

No comments yet — be the first to weigh in on RXRX.

Sign in to join the discussion.

Scroll to Top